Evidence map›Paper›PMID 42214844›Full record

ArticleEBioMedicine2026

Serum proteomics in paediatric inflammatory bowel disease from a case-control study: biomarker discovery and ulcerative colitis-Crohn's disease differentiation.

Mmeyeneabasi Omede, Hasan H Otu, Laurie B Grossberg, Jui-Yen Huang, Xuesong Gu, Simon T Dillon, Handan Can, Tina Lung Morhardt, Catherine Pursley, Harland S Winter and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mmeyeneabasi OmedeCenter for Pediatric Inflammatory Bowel Disease, Mass General Hospital for Children, Pediatric Gastroenterology, Hepatology and Nutrition, Harvard Medical School, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: momede@mgh.harvard.edu.
Hasan H OtuDepartment of Electrical and Computer Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA. Electronic address: hotu2@unl.edu.
Laurie B GrossbergDivision of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: lgrossbe@bidmc.harvard.edu.
Jui-Yen HuangCenter for Pediatric Inflammatory Bowel Disease, Mass General Hospital for Children, Pediatric Gastroenterology, Hepatology and Nutrition, Harvard Medical School, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: jhuang69@mgh.harvard.edu.
Xuesong GuDivision of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: xgu@bidmc.harvard.edu.
Simon T DillonDivision of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sdillon1@bidmc.harvard.edu.
Handan CanDepartment of Electrical and Computer Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA. Electronic address: handancan03@gmail.com.
Tina Lung MorhardtDartmouth Hitchcock Clinics, Manchester, Geisel School of Medicine, Dartmouth, NH, USA. Electronic address: tinaklung@gmail.com.
Catherine PursleyCenter for Pediatric Inflammatory Bowel Disease, Mass General Hospital for Children, Pediatric Gastroenterology, Hepatology and Nutrition, Harvard Medical School, Boston, MA, USA. Electronic address: katiepursley13@gmail.com.
Harland S WinterCenter for Pediatric Inflammatory Bowel Disease, Mass General Hospital for Children, Pediatric Gastroenterology, Hepatology and Nutrition, Harvard Medical School, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: hwinter@mgh.harvard.edu.
Towia A LibermannDivision of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: tliberma@bidmc.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe diagnosis of inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD), relies on clinical and pathological criteria. Non-invasive precision medicine tools to diagnose IBD and discriminate between UC and CD are needed to personalise management. Serum proteomics identified protein biomarkers capable of diagnosing IBD and differentiating CD from UC subtypes.

methodsWe obtained serum samples from a retrospective study of 47 patients with IBD and non-IBD patients seen in a tertiary care paediatric gastroenterology clinic and applied SomaScan proteomics to measure 1305 proteins to discriminate between IBD and non-IBD and UC and CD. Four proteins were further validated by immunoassays in two retrospective cohorts of 295 and 105 individuals and multi-protein predictors were developed using Support Vector Machines (SVM).

findingsThe SomaScan discovery phase identified 95 serum protein biomarkers (BH p < 0.01) that differentiated IBD from non-IBD and 70 proteins (p < 0.01) that distinguished UC from CD. Pathway analysis linked specific inflammatory processes and vascular functions to IBD and UC versus CD. An 8-protein classifier achieved an AUC of 0.95 for identifying IBD. Significant elevation of four key predictor proteins (MMP1, MMP3, Resistin, Haptoglobin) in IBD was validated by ELISA in the expanded cohort (N = 295). The 4-protein SVM predictor achieved an AUC of 0.86 and 0.90 for IBD discrimination in two independent cohorts. A separate 4-protein SVM predictor for differentiating UC from CD achieved an AUC of 0.93 in independent validation.

interpretationPatients with paediatric-onset IBD have a unique serum protein signature associated with pro-inflammatory and vascular pathways. Additional studies are needed to determine whether these dysregulated proteins can be used in conjunction with traditional risk factors to support non-invasive biomarkers that identify IBD and discriminate between its subtypes.

fundingMartin Schlaff, The Diane and Dorothy Brooks Foundation, The Manessis Family, Thomas and Lynn Kuzma, and The Hasso Serrano Foundation.

Indexed as

BiomarkersBlood ProteinsColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesProteomeProteomicsAdolescentCase-Control StudiesChildChild, PreschoolDiagnosis, DifferentialFemaleHumansMaleRetrospective StudiesBiomarkersBlood ProteinsProteomeCrohn's diseaseInflammatory bowel diseasePaediatricsProteomicsSomaScanUlcerative colitis

Identifiers

PMID42214844
PMCPMC13241939

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.